Prognostic Value of PARP1 and PARP2 Copy Number Alterations in Prostate Cancer

  • 0Departament of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Hospital del Mar Research Institute, Barcelona, Spain.

Summary

This summary is machine-generated.

Loss of PARP1 and gain of PARP2 are common in prostate cancer (PCa) and linked to aggressive disease. PARP2 alterations significantly impact prognosis, suggesting copy number analysis can predict PCa outcomes.

Area Of Science

  • Oncology
  • Genetics
  • Molecular Biology

Background

  • Poly (ADP-ribose) polymerase 1/2 (PARP1/2) play roles in DNA repair and androgen receptor regulation.
  • PARP1/2 protein overexpression is linked to resistance to androgen deprivation therapy and prostate cancer (PCa) progression.
  • The prognostic significance of PARP1/2 genomic alterations in PCa remains understudied.

Purpose Of The Study

  • To investigate PARP1/2 copy number alterations in PCa.
  • To assess the prognostic value of these alterations.
  • To explore their potential for therapeutic stratification.

Main Methods

  • Real-time PCR was used to evaluate PARP1/2 copy number status in 121 primary PCa tumors.
  • BRCA1/2 somatic mutations were analyzed in 24 PCa cases.
  • Associations with clinicopathological features, metastasis, and PSA recurrence were assessed.

Main Results

  • PARP1 loss (34.7%) and PARP2 gain (32.2%) were frequent and co-occurred significantly (P < .001).
  • Both alterations correlated with locally advanced disease, metastasis, and aggressive features (Gleason pattern 5, high-grade/stage).
  • Exclusive PARP2 gain was associated with the shortest time to PSA recurrence; wild-type patients had the best outcomes (P = .007).

Conclusions

  • PARP1 loss and PARP2 gain are common, co-occurring alterations associated with PCa aggressiveness.
  • PARP2 alterations significantly impact disease prognosis.
  • PARP1/2 copy number analysis may aid in predicting PCa outcomes and warrants further therapeutic evaluation.